Pregnancy-associated plasma protein-A (PAPP-A) inhibits thrombin-induced coagulation of plasma

Molecular characterization of pregnancy-associated plasma protein-A by electrophoresis

Gradient polyacrylamide gel electrophoresis, isoelectric focusing and multidimensional immunoelectrophoretic techniques have been applied in order to physico-chemically characterize pregnancy-associated plasma protein-A (PAPP-A). By lectin affinity immunoelectrophoresis, PAPP-A contained sialic acid, glucose/mannose and N-acetyl-alpha-D-galactosamine. Immunoelectrophoretic analyses after incubation with various glycolases confirmed these findings and demonstrated that PAPP-A contained glucuronic acid, perhaps in chondroitin sulphate moities, thus indicating that PAPP-A may be a proteoglycan rather than a glycoprotein. Analysis by metal chelate and dye ligand affinity immunoelectrophoresis demonstrated many similarities between PAPP-A and alpha 2-macroglobulin (alpha 2M). However, unlike alpha 2M, PAPP-A did not form immunologically reactive complexes when incubated with proteases. Furthermore, as demonstrated by autoradiographic studies, PAPP-A did not contain internal thiolester groups, thus indicating that PAPP-A cannot inhibit proteases by molecular entrapment and, despite the homotetrameric molecular conformation, PAPP-A and alpha 2M may not have evolved from a common ancestral protein.

Inhibition of thrombin-induced platelet aggregation by uteroglobin

Uteroglobin, a steroid-dependent, small molecular weight (15K) protein in the rabbit, inhibited thrombin-induced aggregation of both rabbit and human gel-filtered platelets (GFP). GFP aggregation by arachidonic acid was not affected by uteroglobin. There were no effects of uteroglobin on thrombin-induced clotting of plasma or purified fibrinogen, or inhibition of thrombin by antithrombin III. Additionally, preliminary results suggest that uteroglobin does not interfere with binding of thrombin to platelets. We suggest that inhibition of platelet aggregation by uteroglobin may function in preventing thrombosis and ensuring free flow of blood through the microvasculature of the uterus and the placenta and may induce some of the antimotility effects of progesterone on the uterus.

New placental proteins: chemistry, physiology and clinical use

In the past decade, several new placental proteins have been isolated and studied. The 'pregnancy-specific' beta 1-glycoprotein (SP1) is a major placental product with unusual physicochemical properties that has been extensively investigated, but its biological function remains uncertain. Pregnancy-associated plasma protein A (PAPP-A), a glycoprotein of mol. wt 400,000, has effects in vitro on the coagulation and complement cascades, probably by its properties of protease inhibition. Placental protein 5 (PP5) may be involved in the coagulation and fibrinolytic systems, and in follicle maturation and semen liquefaction. 'Placental protein 12' (PP12) is not a product of the placenta at all; it appears to be produced in the female genital tract under the influence of progesterone and may also be produced by proliferating liver cells. Further study may reveal new roles for these placental proteins beyond their traditional roles as tumour markers.

In vitro production of pregnancy-associated plasma protein-A (PAPP-A) by trophoblastic cells

Pregnancy-associated plasma protein-A (PAPP-A) a high molecular weight glycoprotein, is found in high concentration in the maternal circulation during pregnancy. Immunohistochemically, PAPP-A can be localized in the trophoblast and in the decidua. Short term cultures of trophoblastic and decidual explants produce PAPP-A in vitro. It was thus of interest to see if long term cultures of primary monolayers of human trophoblast cells were capable of producing PAPP-A. Under our in vitro conditions, trophoblastic monolayers were producing both PAPP-A and beta hCG. During the first 3 days of culture PAPP-A levels increased in the medium whereas beta hCG levels decreased. The production of both proteins could be inhibited by cycloheximide. These results strongly suggest that the trophoblast is a source of PAPP-A in vivo.

The disappearance rate of pregnancy-associated plasma protein-A (PAPP-A) after the end of normal and abnormal pregnancies

PAPP-A is a macromolecular glycoprotein associated with human pregnancy. In vitro, PAPP-A is produced by explant cultures of trophoblast and decidua. The present work was undertaken to see if the presence of decidua had any effect on the disappearance rate of PAPP-A after removal of the placenta either by surgery or by spontaneous delivery. PAPP-A was measured before and at different times after a normal delivery (n = 6), after a termination of early pregnancy (n = 11) and after surgery for ectopic pregnancy (n = 8). The half life of PAPP-A after normal delivery (52.9 +/- 25.8 h, SD) was significantly (p less than 0.03) less than after a first trimester termination (93.9 +/- 41.6 h). After surgery for ectopic pregnancy in patients with curetted decidua, PAPP-A disappeared significantly faster (p less than 0.005) then in patients with intact decidua (84.1 +/- 17.8 vs 241.2 +/- 81.5 h). These results indicate that PAPP-A continues to be produced by the decidua after removal of the trophoblast in early pregnancy.